Charles River provided updated 3-year revenue and margin targets ahead of its investor day event, both of which were below consensus, UBS tells investors in a research note. The analyst, who made no change to the firm’s Buy rating or $255 price target, notes that all segment targets were lowered from the previous long-term targets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRL:
- Charles River says ‘well positioned to deliver 6%-8% organic revenue growth
- Charles River enters multi-program collaboration pact utilizing Logica
- Charles River initiated with a Market Perform at TD Cowen
- Charles River, PathoQuest validate sequencing viral safety assay as option
- Charles River in HQ plasmid manufacturing deal with Fondazione Telethon